Market Overview

Vancive Medical Technologies, CareFusion Sign Agreement for Antimicrobial Dressing


Vancive Medical Technologies™ and CareFusion Corporation (NYSE: CFN)
today announced an exclusive agreement in the United States, Canada and
Mexico for the licensing and distribution of Vancive's BeneHold™
Chlorhexidine Gluconate (CHG) antimicrobial Adhesive Technology for
applications in vascular access.

Under the agreement, CareFusion will market Vancive's unique
antimicrobial adhesive technology used with transparent dressings that
are ideally suited for protection of catheter insertion sites. The first
product received 510(k) clearance from the U.S. Food and Drug
Administration (FDA) in September 2012 and will be co-branded under
CareFusion's new ChloraShield™ brand.

“We are excited about this collaboration, and believe it is an excellent

See full press release

Posted-In: News Guidance Contracts FDA Management Global


Related Articles (AVY + CFN)

View Comments and Join the Discussion!